JWM
BBIO icon

JPL Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

JPL Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86K Buy
+25
New +$1.81K ﹤0.01% 1001
2025
Q4 		– Sell
-25
Closed -$1.3K – 217
2025
Q3 		$1.3K Buy
+25
New +$1.22K ﹤0.01% 956

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JPL Wealth Management's BBIO Position: Q1 2026 in Review

JPL Wealth Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 25 shares worth $1.86K. The stake represents ﹤0.01% of the portfolio and ranks #1001 among its holdings. This is a return to the name: JPL Wealth Management previously reported a position in BBIO as recently as Q3 2025.

JPL Wealth Management first reported a position in BBIO in Q3 2025 and has held it in 2 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • JPL Wealth Management held 25 shares of BridgeBio Pharma worth $1.86K as of Q1 2026.
  • BridgeBio Pharma was a new JPL Wealth Management position in Q1 2026.
  • BridgeBio Pharma made up ﹤0.01% of JPL Wealth Management's portfolio in Q1 2026, its #1001 holding.
  • JPL Wealth Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 2 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on JPL Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.